Evidence map›Paper›PMID 42792909›Full record

ArticleGenes2026

AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with

Takuya Tokunaga, Yuka Ishihara, Aya Harada Takeda, Yuya Tomioka, Ayako Nagata, Mayuko Kato, Takayuki Suetsugu, Keiko Mizuno, Kazuhiro Ueda, Naohiko Seki

Abstract read
In one paragraph

Article in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Takuya TokunagaDepartment of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.ORCID 0009-0008-1885-5775
Yuka IshiharaDepartment of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
Aya Harada TakedaDepartment of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.ORCID 0000-0002-7982-8104
Yuya TomiokaDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.ORCID 0009-0006-7067-5064
Ayako NagataDepartment of Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.ORCID 0000-0001-8735-3383
Mayuko KatoDepartment of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.ORCID 0009-0004-9511-6977
Takayuki SuetsuguDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
Keiko MizunoDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.ORCID 0000-0001-6738-7906
Kazuhiro UedaDepartment of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.ORCID 0000-0003-0030-0882
Naohiko SekiDepartment of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.ORCID 0000-0003-4731-7956

Funding

Japan Society for the Promotion of Science 24K11370Japan Society for the Promotion of Science 24K12457Japan Society for the Promotion of Science 24K12641Japan Society for the Promotion of Science 25K12108
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AcrylamidesAdenocarcinoma of LungAniline CompoundsLung NeoplasmsMicroRNAsProto-Oncogene Proteins c-aktPyrimidinesPyrrolesAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorErbB ReceptorsGene Expression Regulation, NeoplasticHumansIndolesMutationProtein Kinase InhibitorsAcrylamidesAniline CompoundscapivasertibEGFR protein, humanErbB ReceptorsIndolesMicroRNAsMIRN126 microRNA, humanosimertinibProtein Kinase InhibitorsProto-Oncogene Proteins c-aktPyrimidinesPyrrolesAKT2capivasertibEGFR mutationmiR-126-3pmolecular pathwayosimertinib

Identifiers

PMID42792909
PMCPMC13606595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.